<DOC>
	<DOC>NCT02038933</DOC>
	<brief_summary>The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT</brief_summary>
	<brief_title>Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Confirmation of relapsed or refractory DLBCL or transformed lymphoma (TL) Eastern Cooperative Oncology Group (ECOG) performance status of 0 1 At least one lesion that measures &gt;1.5 cm Prior therapy and screening lab criteria must be met Appropriate contraceptive measures must be taken Known central nervous system (CNS) lymphoma History of interstitial lung disease, prior malignancy, active autoimmune disease, positive test for hepatitis B or hepatitis C virus Prior allogeneic stem cell transplant (SCT), chest radiation ≤ 24 weeks from study drug, ≥1000 mg of Carmustine Bischloroethylnitrosourea (BCNU) as part of pretransplant conditioning regimen, prior treatment with drug targeting Tcell costimulation or immune checkpoint pathways Women who are breastfeeding or pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>